A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

Prior treatment

• Have had prior treatment with a passive anti-amyloid immunotherapy.

Other illness

• Have significant neurological disease affecting the central nervous system other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, or epilepsy or recurrent seizures, except febrile childhood seizures.
• Has current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study.
• Have a presence or history of malignant neoplasms within the past 5 years prior to Visit 1.
  • Exceptions:
• non-metastatic basal- or squamous-cell skin cancer
• Stage 0 non-invasive prostate cancer, or
• other cancers with low risk of recurrence or spread

Other

• A life expectancy of \<24 months.
• Contraindication to MRI or PET scans
• Stage 0 non-invasive carcinoma of the cervix

• Gradual and progressive change in memory function reported by the participant or informant for ≥6 months.
• A mini mental state examination (MMSE) score of 20 to 28 (inclusive) at screening.
• Have an amyloid PET scan result from central read, consistent with the presence of amyloid pathology.